Omnitarg Research To Focus on Ovarian Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech will focus development of the HER dimerization inhibitor Omnitarg (pertizumab) on the treatment of ovarian cancer, the biotechnology firm said